2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era.
Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry.
2018 was an active and exciting year in the Atlas portfolio. Six of our portfolio companies went public, the drug developed by Arteaus was approved, we announced our first Opportunity Fund, and so much more. Check out our newsletter for the highlights.
2018 was an incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third of the year was challenging – indices plummeting over 25% in four months.
“It just says ‘High.'”
I winced. My patient, a man with type 1 diabetes who had emigrated from Latin America two weeks earlier, was reading a finger prick result on his blood sugar meter to me over the phone. Normal blood sugar ranges between 70 and 100. Beyond 600, the meter loses accuracy and spits out an understated “High” instead of an actual number. I knew what this seemingly innocuous message meant: My patient was at risk for serious, even deadly complications from a critically high blood sugar. And I had known there was a chance his blood sugar would spike when I switched his insulin regimen.